Health In Tech vs Roadzen
HIT and RDZN side by side, both in insurance agents, brokers, and service. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HIT and RDZN compare
Roadzen is the larger company, worth 3.2 times as much as Health In Tech ($82.8M against $25.9M).
Roadzen grew revenue faster over the last twelve months (30.5% versus 0.65% for Health In Tech).
Health In Tech keeps more of each dollar of sales as profit, with a net margin of −37.1% compared with −46.9% at Roadzen.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HIT | RDZN |
|---|---|---|
| Size and price | ||
| Market cap | $25.9M | $82.8M |
| Share price | $0.396 | $0.972 |
| Change, 1 year | −78.4% | −31.0% |
| Beta (5Y) | 1.29 | 0.78 |
| Employees | 87 | 458 |
| StockData Score | ||
| Total score | 2 | 2 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 1 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.8× (better) | 1.4× |
| Growth | ||
| Revenue growth (TTM) | 0.65% | 30.5% (better) |
| Net income growth (TTM) | −898% | – |
| EPS growth (TTM) | −733% | – |
| Profitability | ||
| Gross margin | 50.5% | 60.7% (better) |
| Operating margin | – | −21.6% |
| Net margin | −37.1% (better) | −46.9% |
| Return on equity | −66.8% | – |
| Financial health | ||
| Current ratio | 1.13 (better) | 0.45 |
| Altman Z-score | 1.92 (better) | −7.33 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | – | −15.2% |
| Shareholder yield | 0.00% (better) | −15.2% |
| Ownership | ||
| Held by institutions | 7.1% | – |
| Held by insiders | 76.6% | 23.8% |
| Insider net buying, 12 months | −$40.6K | $43.2K (better) |
| Short interest, % of float | 3.9% | – |
Go deeper
- HIT stock overview
- HIT income statement
- HIT valuation and score
- RDZN stock overview
- RDZN income statement
- RDZN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.